Terms: = Lung cancer AND MAP2K1, MAPKK1, 5604, ENSG00000169032, Q02750, MEK1, MKK1, PRKMK1
323 results:
1. Clonal expansion of shared T cell receptors reveals the existence of immune commonality among different lesions of synchronous multiple primary lung cancer.
Wang Y; Huang Z; Li B; Xue J; Guo C; Bing Z; Zheng Z; Song Y; Xu Y; Huang G; Li H; Yu X; Xia Y; Li R; Si X; Zhang L; Li J; Song L; Xiong Y; Gu D; Song M; Zhou Z; Chen R; Feng Z; Bie Z; Li X; Yang H; Li S; Liang N
Cancer Immunol Immunother; 2024 Apr; 73(6):111. PubMed ID: 38668781
[TBL] [Abstract] [Full Text] [Related]
2. Gefitinib Induces Apoptosis in NSCLC Cells by Promoting Glutaminolysis and Inhibiting the MEK/ERK Signaling Pathway.
Zhang Y; Liu H; Liu X; Lang L
Discov Med; 2024 Apr; 36(183):836-841. PubMed ID: 38665031
[TBL] [Abstract] [Full Text] [Related]
3. Tet methylcytosine dioxygenase 2 (TET2) deficiency elicits EGFR-TKI (tyrosine kinase inhibitors) resistance in non-small cell lung cancer.
Zhang J; Zhao K; Zhou W; Kang R; Wei S; Shu Y; Yu C; Ku Y; Mao Y; Luo H; Yang J; Mei J; Pu Q; Deng S; Zha Z; Yuan G; Shen S; Chen Y; Liu L
Signal Transduct Target Ther; 2024 Mar; 9(1):65. PubMed ID: 38461173
[TBL] [Abstract] [Full Text] [Related]
4. lung Fibroblasts Take up Breast cancer Cell-derived Extracellular Vesicles Partially Through MEK2-dependent Macropinocytosis.
Wan Y; Zhao Y; Cao M; Wang J; Tran SV; Song Z; Hsueh BW; Wang SE
Cancer Res Commun; 2024 Jan; 4(1):170-181. PubMed ID: 38259097
[TBL] [Abstract] [Full Text] [Related]
5. Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update.
Roskoski R
Pharmacol Res; 2024 Feb; 200():107059. PubMed ID: 38216005
[TBL] [Abstract] [Full Text] [Related]
6. Identification of Bulbocodin D and C as novel STAT3 inhibitors and their anticancer activities in lung cancer cells.
He X; Fu J; Lyu W; Huang M; Mo J; Cheng Y; Xu Y; Zheng L; Zhang X; Qi L; Zhang L; Zheng Y; Huang M; Ni L; Lu J
Chin J Nat Med; 2023 Nov; 21(11):842-851. PubMed ID: 38035939
[TBL] [Abstract] [Full Text] [Related]
7. Selumetinib overcomes gefitinib primary and acquired resistance by regulating MIG6/STAT3 in NSCLC.
Song X; Wang L; Tang W; Yuan L; Liu Q; Li J; Fan D
Arch Pharm Res; 2023 Dec; 46(11-12):924-938. PubMed ID: 38032449
[TBL] [Abstract] [Full Text] [Related]
8. Multi-gene Liquid Biopsy to Detect Resistance to First-line Osimertinib in Patients With
Ito S; Tsurumi K; Shindo N; Soma S; Yamaguchi K; Tamai K; Mochizuki M; Fujimori H; Morita M; Watanabe K; Suzuki A; Fukuhara T; Yasuda J
Anticancer Res; 2023 Nov; 43(11):5031-5040. PubMed ID: 37909987
[TBL] [Abstract] [Full Text] [Related]
9. Bruceine A: Suppressing metastasis via MEK/ERK pathway and invoking mitochondrial apoptosis in triple-negative breast cancer.
Li X; Liu C; Zhang X; Sun C; Ling J; Liu Y; Zuo Y; Cao Y; Zhang C; Jiang T; Wang M; Liu J; Lu J
Biomed Pharmacother; 2023 Dec; 168():115784. PubMed ID: 37879215
[TBL] [Abstract] [Full Text] [Related]
10. Signature-driven repurposing of Midostaurin for combination with mek1/2 and KRASG12C inhibitors in lung cancer.
Macaya I; Roman M; Welch C; Entrialgo-Cadierno R; Salmon M; Santos A; Feliu I; Kovalski J; Lopez I; Rodriguez-Remirez M; Palomino-Echeverria S; Lonfgren SM; Ferrero M; Calabuig S; Ludwig IA; Lara-Astiaso D; Jantus-Lewintre E; Guruceaga E; Narayanan S; Ponz-Sarvise M; Pineda-Lucena A; Lecanda F; Ruggero D; Khatri P; Santamaria E; Fernandez-Irigoyen J; Ferrer I; Paz-Ares L; Drosten M; Barbacid M; Gil-Bazo I; Vicent S
Nat Commun; 2023 Oct; 14(1):6332. PubMed ID: 37816716
[TBL] [Abstract] [Full Text] [Related]
11. Cellular responses after (neratinib plus pemetrexed) exposure in NSCLC cells.
Booth L; Poklepovic A; Hancock JF; Dent P
Anticancer Drugs; 2023 Oct; 34(9):1025-1034. PubMed ID: 37703296
[TBL] [Abstract] [Full Text] [Related]
12. Pulmonary Langerhans cell histiocytosis - an update on pathogenesis and treatment.
Jouenne F; Benattia A; Tazi A
Curr Opin Pulm Med; 2023 Sep; 29(5):451-458. PubMed ID: 37410483
[TBL] [Abstract] [Full Text] [Related]
13. Resistance to KRAS G12C Inhibition in Non-small Cell lung cancer.
Di Federico A; Ricciotti I; Favorito V; Michelina SV; Scaparone P; Metro G; De Giglio A; Pecci F; Lamberti G; Ambrogio C; Ricciuti B
Curr Oncol Rep; 2023 Sep; 25(9):1017-1029. PubMed ID: 37378881
[TBL] [Abstract] [Full Text] [Related]
14. The phospholipid transporter PITPNC1 links KRAS to MYC to prevent autophagy in lung and pancreatic cancer.
Entrialgo-Cadierno R; Cueto-Ureña C; Welch C; Feliu I; Macaya I; Vera L; Morales X; Michelina SV; Scaparone P; Lopez I; Darbo E; Erice O; Vallejo A; Moreno H; Goñi-Salaverri A; Lara-Astiaso D; Halberg N; Cortes-Dominguez I; Guruceaga E; Ambrogio C; Lecanda F; Vicent S
Mol Cancer; 2023 May; 22(1):86. PubMed ID: 37210549
[TBL] [Abstract] [Full Text] [Related]
15. Trametinib in Patients With
Wisinski KB; Flamand Y; Wilson MA; Luke JJ; Tawbi HA; Hong F; Mitchell EP; Zwiebel JA; Chen H; Gray RJ; Li S; McShane LM; Rubinstein LV; Patton D; Williams PM; Hamilton SR; Behrens RJ; Pennington KP; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
JCO Precis Oncol; 2023 Apr; 7():e2200421. PubMed ID: 37053535
[TBL] [Abstract] [Full Text] [Related]
16. The heterogeneous transition state of resistance to RET kinase inhibitors converges on ERK1/2-driven Aurora A/B kinases.
Hu X; Liu X; Khatri U; Wu J
Drug Resist Updat; 2023 May; 68():100958. PubMed ID: 36990046
[TBL] [Abstract] [Full Text] [Related]
17. Combination of the LARS1 Inhibitor, BC-LI-0186 with a mek1/2 Inhibitor Enhances the Anti-Tumor Effect in Non-Small Cell lung cancer.
Lee SH; Kim EY; Han JM; Han G; Chang YS
Cancer Res Treat; 2023 Jul; 55(3):851-864. PubMed ID: 36960627
[TBL] [Abstract] [Full Text] [Related]
18. Comprehensive characterization of B7 family members in NSCLC and identification of its regulatory network.
Xiao M; Pang C; Xiang S; Zhao Y; Wu X; Li M; Du F; Chen Y; Wang F; Wen Q; Xiao Z; Yang Z; Shen J
Sci Rep; 2023 Mar; 13(1):4311. PubMed ID: 36922519
[TBL] [Abstract] [Full Text] [Related]
19. Rare molecular subtypes of lung cancer.
Harada G; Yang SR; Cocco E; Drilon A
Nat Rev Clin Oncol; 2023 Apr; 20(4):229-249. PubMed ID: 36806787
[TBL] [Abstract] [Full Text] [Related]
20. Target Identification of 22-(4-Pyridinecarbonyl) Jorunnamycin A, a Tetrahydroisoquinoline Derivative from the Sponge
Iksen I; Sinsook S; Wattanathamsan O; Buaban K; Chamni S; Pongrakhananon V
Molecules; 2022 Dec; 27(24):. PubMed ID: 36558080
[TBL] [Abstract] [Full Text] [Related]
[Next]
